Here, the remarkable transformation of Janus kinase (JAK) inhibitors is discussed, from their initial approval for the treatment of hematologic cancer in 2010 to their current use in treating various dermatologic diseases. JAK inhibitors have shown efficacy in conditions like alopecia areata, vitiligo, atopic dermatitis, psoriasis, lichen planus, and granuloma annulare, among others.
Dr. Brett A. King, associate professor of dermatology at the Yale School of Medicine, reports on the evolution of JAK inhibitors, the implications it has in dermatology, off-label uses and mechanisms, and management of risks and benefits.